Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]
News [4645]
Articles [192]
Editorials [8]
Conferences [136]
elearning [9]
Teamwork in cancer care
Dr Soumitra Shankar Datta - Tata Medical Centre, Kolkata, India
Teamwork in cancer care ( Dr Soumitra Shankar Datta - Tata Medical Centre, Kolkata, India )
13 Jan 2022
Dihydropyrimidine dehydrogenase polymorphisms knocking on the door
Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil
Dihydropyrimidine dehydrogenase polymorphisms knocking on the door ( Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil )
11 Jan 2022
Frontline treatment with single agent pembrolizumab followed by AVD...
Prof Pamela Allen - Emory University School of Medicine, Georgia, USA
Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )
22 Dec 2021
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
22 Dec 2021
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer...
Dr Sara Hurvitz - University of California, Los Angeles, USA
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ( Dr Sara Hurvitz - University of California, Los Angeles, USA )
21 Dec 2021
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib +...
Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease ( Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA )
21 Dec 2021
The RxPONDER trial and its impact on best clinical practice
Prof Christos Markopoulos and Prof Giuseppe Curigliano
The RxPONDER trial and its impact on best clinical practice ( Prof Christos Markopoulos and Prof Giuseppe Curigliano )
17 Dec 2021
WHO and St. Jude Children’s research hospital to dramatically increase global...
Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer...
WHO and St. Jude Children’s research hospital to dramatically increase global access to childhood cancer medicine ( Dr Andre Llbawi - World Health Organization (WHO) Global Childhood Cancer Initiative )
17 Dec 2021
The global platform for access to childhood cancer medicines
Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA
The global platform for access to childhood cancer medicines ( Dr James Downing - St. Jude Children’s Research Hospital, Memphis, USA )
17 Dec 2021
Cancer medicine shortages for children around the world
Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis...
Cancer medicine shortages for children around the world ( Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA )
17 Dec 2021
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
14 Dec 2021
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for...
Dr Michael Bishop - University of Chicago, Chicago, USA
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )
14 Dec 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation